Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study.
Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study.
复制标题
DOI：
10.1136/bmjopen-2021-053487
复制
发表时间：
2021-11-18
期刊：
影响因子：
2.9
通讯作者：
Raji MA
中科院分区：
文献类型：
--
作者：
Esechie A;Kuo YF;Goodwin JS;Westra J;Raji MA
Opioid and benzodiazepine co-prescribing is associated with a substantial increase in opioid overdose deaths. In this study, we examine the prescribing trends of substitutes of opioids and benzodiazepines alone or in combination, compared with opioids and benzodiazepines. Retrospective cohort study. Data were collected using a 20% national sample of Medicare beneficiaries from 2013 to 2018. 4.1–4.3 million enrollees each year from 2013 to 2018. None. We employ a generalised linear mixed models to calculate ORs for opioid use, benzodiazepine or Z-drug (benzos/Z-drugs) use, opioid/benzos/Z-drugs 30-day use, gabapentinoid use and (selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRIs)) use, adjusted for the repeated measure of patient. We then created two models to calculate the ORs for each year and comparing to 2013. Opioid and benzos/Z-drugs use decreased by 2018 (aOR 0.626; 95% CI 0.622 to 0.630) comparing to 2013. We demonstrate a 36.3% and 9.9% increase rate of gabapentinoid and SSRI/SNRI use, respectively. Furthermore, combined gabapentinoid and SSRI/SNRI use increased in 2018 (aOR 1.422; 95% CI 1.412 to 1.431). Little is known about the prescribing pattern and trend of opioid and benzodiazepine alternatives as analgesics. There is a modest shift from prescribing opioid and benzos/Z-drugs (alone or in combination) towards prescribing non-opioid analgesics—gabapentinoids with and without non-benzos/Z-drugs that are indicated for anxiety. It is unclear if this trend towards opioid/benzos/Z-drugs alternatives is associated with fewer drug overdose death, better control of pain and comorbid anxiety, and improved quality of life.
登录
查看更多内容
抗抑郁药治疗神经性疼痛的镇痛机制
影响因子：
5.6
作者：
Obata H
通讯作者：
Obata H
慢性疼痛综合症药理管理中阿片类药物的替代方法：对随机，控制和盲目临床试验的叙事回顾。
影响因子：
5.7
作者：
Nicol AL;Hurley RW;Benzon HT
通讯作者：
Benzon HT
影响因子：
2.7
作者：
Cunningham JL;Craner JR;Evans MM;Hooten WM
通讯作者：
Hooten WM
DOI：
10.3390/ijerph17020414
发表时间：
2020-01-02
影响因子：
--
作者：
Kascakova, Natalia;Furstova, Jana;Tavel, Peter
通讯作者：
Tavel, Peter
影响因子：
13.8
作者：
Peahl, Alex F.;Dalton, Vanessa K.;Waljee, Jennifer F.
通讯作者：
Waljee, Jennifer F.